1. No guts, no loss: toward the ideal treatment for obesity in the twenty-first century;Hope;Front. Endocrinol. (Lausanne).,2018
2. Gut peptide agonism in the treatment of obesity and diabetes;Grandl;Compr. Physiol.,2020
3. Newer pharmacological interventions directed at gut hormones for obesity;Camilleri;Br. J. Pharmacol.,2023
4. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes, (2022). 〈https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes〉 (accessed January 29, 2024).
5. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP;Theodorakis;Am. J. Physiol. - Endocrinol. Metab.,2006